Dyne Therapeutics (DYN) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 9, 2026

Net selling: insiders sold $65.7M and bought $40K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: -$65.6M net
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Jun 30, 2026: 3 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about DYN filings

Are insiders buying or selling Dyne Therapeutics Inc (DYN) stock?

Net selling: insiders sold $65.7M and bought $40K of DYN stock on the open market in the 90 days to Nov 9, 2026, according to SEC Form 4 filings. $65.7M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Rhodes, Jason P (Director), who sold $65.2M. The latest filing was on Oct 6, 2026.

Which members of Congress have traded DYN recently?

None. No member of Congress disclosed a DYN trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this DYN smart-money data?

This summary uses filings available on Nov 9, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on DYN

Lean long1 source:
- Funds
Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
Lean short1 buy · 2 sales
2 of 3 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
Lean long3 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about DYN filings

Are insiders buying or selling Dyne Therapeutics Inc (DYN) stock?

Which members of Congress have traded DYN recently?

None. No member of Congress disclosed a DYN trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this DYN smart-money data?

Funds

What funds are doing

4 moves · 6 mo

Buys/Adds$85.7M

Buys/Adds (3)

CI
Citadel
Ken Griffin · Q2 2026 13F
$21.8M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%
MW
Marshall Wace
Q2 2026 13F
$31.6M
added
BO
Bank of America
Q2 2026 13F
$23.4M
added

1 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 1 moves

Other smart money signals

Activist stakes, short interest & more

1 item

SI
Short Interest ChangeModerate
short-volume tape softening: latest 39.0% fell 10.4pp vs 19d avg 49.4%

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 5, 2026

Earnings came in 20.2% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 5, 2026

Period ending

Sep 30, 2026

Earnings per share

-$1.06-20.20% miss

-$0.88 expected

Revenue

$0.00

SEC filing · No operating revenue

EPS: Yahoo Finance

Next report

What the street expects next

Estimates as of Nov 9, 2026

EPS expected

-$0.91

-$1.11 to -$0.58

Last 30 days

0up1down

Analysts cutting estimates

Estimate drift

0.02

Change in 30 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 5, 2026	-$1.06est. -$0.88	-20.20%miss	$0.00SEC filing	No year-ago quarter
Jun 30, 2026Reported Jul 29, 2026	-$1.08est. -$0.75	-44.28%miss	$0.00SEC filing	No year-ago quarter
Mar 31, 2026Reported May 11, 2026	-$0.73est. -$0.78	+6.65%beat	$0.00Alpha Vantage	No year-ago quarter
Dec 31, 2025Reported Mar 2, 2026	-$0.73est. -$0.76	+4.41%beat	$0.00Alpha Vantage	-100.0%from $1.6M
Sep 30, 2025Reported Nov 5, 2025	-$0.76est. -$0.81	+6.17%beat	$0.00Alpha Vantage	No year-ago quarter
Jun 30, 2025Reported Jul 28, 2025	-$0.97est. -$0.93	-4.30%miss	$0.00Alpha Vantage	No year-ago quarter
Mar 31, 2025Reported May 8, 2025	-$1.05est. -$0.84	-25.00%miss	$0.00Alpha Vantage	No year-ago quarter
Dec 31, 2024Reported Feb 27, 2025	-$0.88est. -$0.91	+3.51%beat	$1.6MAlpha Vantage	-58.5%from $3.8M

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $17.68
High: $18.33
Low: $17.40
Prev close: $17.36
52-wk high: $27.30
52-wk low: $14.00
Mkt cap: $3.39B
ROE: -81.6%
Beta: 1.21
P/B: 3.6x
Profit margin: +0.0%
Op margin: +0.0%

Dec 2025 to Sep 2026

What it sold, what it cost, what was left.

RevenueProfit

Dec 2025Mar 2026Jun 2026Sep 2026

Income statement, 4 periods, all values in US dollars
USD	Dec 2025	Mar 2026	Jun 2026	Sep 2026
What came in
RevenueTotal revenue	$0	$0	$0	$0
Cost of what it soldCost of revenue	$521.0K	$550.0K	—	—
Gross profit	-$521.0K	-$550.0K	—	—
What it spent
Research and development	$95.4M	$100.9M	$152.2M	$161.7M
Sales and adminSelling, general and administrative	$20.7M	$24.4M	$29.5M	$35.3M
Total operating expenses	$115.6M	$125.3M	$181.7M	$197.1M
What was left
Operating profitOperating income	-$116.1M	-$125.3M	-$181.7M	-$197.1M
Interest on debtInterest expense	$3.2M	$4.2M	$4.6M	$5.9M
Profit before tax	-$112.0M	-$120.9M	-$178.6M	-$193.6M
Net profitNet income	-$112.0M	-$120.9M	-$178.6M	-$193.6M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$101.2M	-$116.1M	-$173.4M	-$187.0M

Technicals

Price structure

This stock is trending upward.

Trend

Constructive

75 / 100

RSI 14

70balanced

20D volatility

67%annualized

52-week range

$18.07

$14.00$27.30

20D support

$14.13recent floor

20D resistance

$19.00recent ceiling

Returns

5D +8.3%20D +8.6%60D -30.4%

Price vs moving averages

SMA20 +10.4%SMA50 +2.1%SMA200 -6.5%

Volume pace

0.76xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 5, 2026

-$1.06est. -$0.88

-20.20%

$0.00SEC filing

No year-ago quarter

Jun 30, 2026Jul 29, 2026

-$1.08est. -$0.75

-44.28%

$0.00SEC filing

No year-ago quarter

Mar 31, 2026May 11, 2026

-$0.73est. -$0.78

+6.65%

$0.00Alpha Vantage

No year-ago quarter

Dec 31, 2025Mar 2, 2026

-$0.73est. -$0.76

+4.41%

$0.00Alpha Vantage

-100.0%from $1.6M

Sep 30, 2025Nov 5, 2025

-$0.76est. -$0.81

+6.17%

$0.00Alpha Vantage

No year-ago quarter

Jun 30, 2025Jul 28, 2025

-$0.97est. -$0.93

-4.30%

$0.00Alpha Vantage

No year-ago quarter

Mar 31, 2025May 8, 2025

-$1.05est. -$0.84

-25.00%

$0.00Alpha Vantage

No year-ago quarter

Dec 31, 2024Feb 27, 2025

-$0.88est. -$0.91

+3.51%

$1.6MAlpha Vantage

-58.5%from $3.8M

Income statement, 4 periods, all values in US dollars
USD	Dec 2025	Mar 2026	Jun 2026	Sep 2026
What came in
RevenueTotal revenue	$0	$0	$0	$0
Cost of what it soldCost of revenue	$521.0K	$550.0K	—	—
Gross profit	-$521.0K	-$550.0K	—	—
What it spent
Research and development	$95.4M	$100.9M	$152.2M	$161.7M
Sales and adminSelling, general and administrative	$20.7M	$24.4M	$29.5M	$35.3M
Total operating expenses	$115.6M	$125.3M	$181.7M	$197.1M
What was left
Operating profitOperating income	-$116.1M	-$125.3M	-$181.7M	-$197.1M
Interest on debtInterest expense	$3.2M	$4.2M	$4.6M	$5.9M
Profit before tax	-$112.0M	-$120.9M	-$178.6M	-$193.6M
Net profitNet income	-$112.0M	-$120.9M	-$178.6M	-$193.6M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$101.2M	-$116.1M	-$173.4M	-$187.0M

USD

Dec 2025

Mar 2026

Jun 2026

Sep 2026

What came in

RevenueTotal revenue

Cost of what it soldCost of revenue

$521.0K

$550.0K

—

Gross profit

-$521.0K

-$550.0K

—

What it spent

Research and development

$95.4M

$100.9M

$152.2M

$161.7M

Sales and adminSelling, general and administrative

$20.7M

$24.4M

$29.5M

$35.3M

Total operating expenses

$115.6M

$125.3M

$181.7M

$197.1M

What was left

Operating profitOperating income

-$116.1M

-$125.3M

-$181.7M

-$197.1M

Interest on debtInterest expense

$3.2M

$4.2M

$4.6M

$5.9M

Profit before tax

-$112.0M

-$120.9M

-$178.6M

-$193.6M

Net profitNet income

-$112.0M

-$120.9M

-$178.6M

-$193.6M

EBITDAEarnings before interest, tax, depreciation, amortisation

-$101.2M

-$116.1M

-$173.4M

-$187.0M

Dyne Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about DYN filings

Smart money on DYN

Questions about DYN filings

What funds are doing

What insiders are doing

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Earnings came in 20.2% below what analysts expected.

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Dyne Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about DYN filings

Smart money on DYN

Questions about DYN filings

What funds are doing

What insiders are doing

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Earnings came in 20.2% below what analysts expected.

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Dyne Therapeutics Inc

Overview

Questions about DYN filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Dyne Therapeutics Inc

Overview

Questions about DYN filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.